Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTSH for RAI Remnant Ablation in Differentiated Thyroid Cancer
NCT04447183Phase 2Completed
- Sponsor
- Zelgen
- Start
- Nov 2020
- Primary completion
- May 2022
- Modality
- Biologic, rProtein (Recombinant Protein), Hormone
- Countries
- 1
01
Overview
A Phase 2 trial of thyrotropin alfa in differentiated thyroid cancer (DTC), sponsored by Zelgen. Started Nov 2020; status: completed.
02
Drugs
thyrotropin alfa
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT04447183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04447183.